Polypodium leucotomos
Polypodium leucotomos (Fernblock)
Oral fern antioxidant that boosts skin's UV tolerance
Moderate evidence
✨Joint & Skin
Evidence tier
Moderate
Research weight
Citations
18 verified / 18
Classification
Joint & Skin
❝
What the evidence says. Several controlled trials; effects real but modest or context-dependent.
What is Polypodium leucotomos?
Polypodium leucotomos (Polypodium leucotomos (Fernblock)) is a joint and skin supplement used for raises minimal erythema dose (less sunburn redness). NutriDex grades the human evidence as Moderate. Polypodium leucotomos extract (marketed as Fernblock) is an oral antioxidant from a tropical fern, rich in phenolic acids. Human studies show it can raise the minimal erythema dose (MED) and reduce UV-induced erythema, indicating modest systemic photoprotection. It raised the UV threshold for provoking polymorphic light eruption in an open study, and a randomized melasma trial found it modestly improved pigmentation when added to hydroquinone and SPF 50+. It is an adjunct, NOT a replacement for sunscreen, and supporting trials are generally small and sometimes uncontrolled.
Purported Benefits
✓Raises minimal erythema dose (less sunburn redness)
✓Adjunct for polymorphic light eruption
✓May aid melasma alongside hydroquinone + SPF
✓Systemic antioxidant vs UV damage
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Photoprotection (raised MED / reduced UV erythema)Multiple small RCTs and systematic reviews consistently show raised minimal erythema dose; adjunct only, not a sunscreen replacement. | Moderate | ↑ benefit · moderate | 4 |
| Melasma (adjunct to hydroquinone + SPF)Several small double-blind RCTs show modest extra MASI reduction added to standard care; pilot-sized samples. | Moderate | ↑ benefit · small | 3 |
| Polymorphic light eruption / photodermatosesOpen, uncontrolled studies raised UV provocation threshold; lack of blinding/controls limits certainty. | Preliminary | ↑ benefit · moderate | 2 |
| Vitiligo repigmentation (adjunct to NB-UVB)Two placebo-controlled RCTs show higher repigmentation response added to NB-UVB; modest sample sizes. | Moderate | ↑ benefit · moderate | 2 |
| Actinic keratosis / field cancerization (adjunct)Single multicentre RCT in severe actinic damage showed fewer new lesions; needs replication. | Preliminary | ↑ benefit · small | 1 |
Dosing & Compounds
Typical Dose
240–480 mg/day orally (often taken before sun exposure).
Active Compounds
Safety & Cautions
Well tolerated short-term with only occasional mild GI upset; long-term and pregnancy data are limited. Critically, it is an ADJUNCT and does NOT replace sunscreen, protective clothing, or sun avoidance — its photoprotection is only partial. Educational only — always check with your doctor or pharmacist before combining Polypodium leucotomos with any medicine.
Key Studies ★ 18 studies
systematic review
Zundell/Zakria 2025 (systematic review)
✓ PubMed
Systematic review of 21 studies (11 RCTs) found oral Polypodium leucotomos extract has photoprotective and immunomodulatory effects and serves as a beneficial adjuvant in photoaging, photodermatoses, melasma, vitiligo, psoriasis, and atopic dermatitis, with a strong safety profile.
systematic review
Natarelli 2025 (systematic review)
✓ Full text
Systematic review of 47 studies on oral photoprotective supplements concluded the strongest evidence exists for polyphenols, carotenoids, and Polypodium leucotomos, which consistently raised minimal erythema dose and reduced UV-induced skin damage in healthy adults.
Systematic review
Natarelli 2025
✓ PubMed
Systematic review of 47 human studies on oral photoprotective supplements concluded the strongest evidence of photoprotection exists for polyphenols, carotenoids, and Polypodium leucotomos.
Systematic review
Rodriguez-Luna 2025 — Actas Dermosifiliogr systematic review
✓ PubMed
PRISMA systematic review (PROSPERO-registered; 21 studies 2013-2023) of oral nutraceuticals for actinic keratosis and field cancerization. Concludes clinical trials demonstrate the efficacy of polyphenolic supplements including Polypodium leucotomos extract in improving skin health and reducing skin-cancer risk. (Source: PubMed)
systematic review
Choudhry 2014 (systematic review)
✓ Source
Systematic review of 18 human studies (Medline, Embase, Cochrane), predominantly using Fernblock/Heliocare, found oral Polypodium leucotomos extract consistently produced photoprotective effects (increased minimal erythema dose) with a favorable safety profile.
RCT
Keršmanc 2025 (RCT)
✓ Full text
Randomized double-blind placebo-controlled trial (54 adults); 8 weeks of combined red orange and Polypodium leucotomos extract supplementation raised minimal erythema dose by 23.8% (p<0.05) and cut UVB-induced erythema intensity by 46.2% (p<0.0001).
RCT
Pellacani 2023 — Photodermatol Photoimmunol Photomed RCT
✓ PubMed
Prospective, multicentre, randomized, three-arm trial (n=131) in older adults with severe actinic damage. Adding oral Fernblock (PLE) to topical photoprotection reduced new actinic keratosis lesions and field-cancerization parameters, with reflectance confocal microscopy showing keratinocyte-layer normalization; combined topical+oral outperformed topical alone. (Source: PubMed)
RCT
Kersmanc 2025 — Nutrients RCT
✓ PubMed
Randomized, double-blind, placebo-controlled trial (n=54, phototypes I-III) of an 8-week PLE + red orange extract + vitamins A/C/D/E supplement. Intervention group showed a significant 23.8% increase in minimal erythema dose and a 46.2% reduction in UVB-induced erythema versus placebo, without affecting tanning. (Source: PubMed)
RCT
Pacifico 2021 (RCT)
✓ PubMed
Randomized placebo-controlled trial (44 generalized vitiligo patients); 480 mg oral PLE twice daily added to NB-UVB for 6 months raised the response rate to 47.8% versus 22% with NB-UVB plus placebo.
RCT
Goh 2018 (RCT)
✓ Source
Double-blind RCT (40 women with melasma); 480 mg PLE twice daily for 12 weeks added to 4% hydroquinone + SPF 50+ gave greater mMASI reduction (54.9% vs 44.4% placebo).
RCT
Nestor 2015 (RCT)
✓ PubMed
Randomized double-blind placebo-controlled trial in healthy adults (Fitzpatrick I-IV); 240 mg oral PLE twice daily for 60 days made subjects ~22-fold more likely to show an increased minimal erythema dose (8 vs 1, p=0.01) and ~15-fold more likely to have reduced UV-induced erythema, with no safety changes.
RCT
Goh 2018 — JCAD melasma RCT (Asian skin)
✓ PubMed
Double-blind, placebo-controlled pilot RCT (n=40) of oral PLE added to topical 4% hydroquinone and SPF50+ in Asian melasma patients. PLE significantly lowered modified MASI versus placebo at 8 and 12 weeks, accelerating improvement from the first month, with improved MelasQoL and no significant side effects. (Source: PubMed)
RCT
Ahmed (Pandya) 2013 — JAMA Dermatology RCT
✓ PubMed
Landmark randomized, double-blind, placebo-controlled trial of oral PLE 240 mg twice daily as an adjunct to SPF45 sunscreen in epidermal melasma. PLE group showed a greater reduction in Melasma Area and Severity Index (MASI) than placebo, with no significant adverse effects, supporting oral PLE as a sunscreen adjunct. (Source: PubMed)
RCT
Middelkamp-Hup 2007 (RCT)
✓ PubMed
Randomized double-blind placebo-controlled trial (50 vitiligo vulgaris patients); oral Polypodium leucotomos plus NB-UVB twice weekly increased head/neck repigmentation versus placebo (44% vs 27%; 50% vs 19% in compliant patients, P<0.002).
review
Rodriguez-Luna 2023 (review)
✓ Full text
Narrative clinical review of standardized PLE (Fernblock) summarizing oral and topical use across photodermatoses, pigmentary disorders, and as an adjunct to photodynamic therapy for actinic keratoses/field cancerization, reporting consistent photoprotective and antioxidant benefit with a strong safety record.
review
Calzari 2023 (review)
✓ Full text
Review of PLE in oncodermatology describing its antioxidant, photoprotective, antimutagenic, anti-inflammatory and immunoregulatory actions supporting prevention of skin cancers and photoaging when taken orally and/or applied topically.
Clinical study
Tanew 2012 (clinical study)
✓ PubMed
Open study in 35 patients with polymorphic light eruption; oral PL significantly raised the UV exposure needed to provoke lesions (UVA p=.005; UVB p=.047).
Clinical study
Caccialanza 2011 (clinical study)
✓ PubMed
Open study in 57 patients with idiopathic photodermatoses; 480 mg/day reduced skin reaction/symptoms in ~74% (P<0.05), no side effects reported.